Differential chemokine expression in chronic GVHD of the conjunctiva

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1340-1346

  Westekemper, H ^a   Meller, S ^b   Citak, S ^a   Schulte, C ^a   Steuhl, K P ^a   Homey, B ^b   Meller, D ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

chemokine; conjunctiva; CXCL10; CXCL9; CXCR3; GVHD

Indexed keywords

BUSULFAN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA A ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; CORNEA ULCER; CYTOLOGY; DRUG MEGADOSE; GENE EXPRESSION PROFILING; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINIZATION; MEIBOMIAN GLAND; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; TEAR FILM; TH1 CELL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CHEMOKINES; CHRONIC DISEASE; CONJUNCTIVAL DISEASES; FEMALE; GENE EXPRESSION PROFILING; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; TH1 CELLS; YOUNG ADULT;

EID: 77955577504     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.346     Document Type: Article

References (44)

1. Dickinson A, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 517-525. (Pubitemid 41207956)
2. Fraser C, Scott Baker K. The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007; 138: 131-145.
3. Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
4. Jabs D, Wingard J, Green W, Farmer E, Vogelsang G, Saral R. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107: 1343-1348. (Pubitemid 19229080)
5. Auw-Haedrich C, Potsch C, Bohringer D, Mittelviefhaus H, Maier P, Reinhard T et al. Histological and immunohisto- chemical characterisation of conjunctival graft vs host disease following haematopoietic stem cell transplantation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1001-1007.
6. Couriel D, Carpenter P, Cutler C, Bolanos-Meade J, Treister N, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375-396.
7. Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83: 1125-1130.
8. Adrean S, Puklin J. Perforated corneal ulcer with subsequent endophthalmitis in a patient with graft-versus-host disease. Cornea 2007; 26: 107-108.
9. Heinz C, Steuhl K, Meller D. Corneal perforation associated with vitamin-A-deficiency. Ophthalmologe 2004; 101: 614-617.
10. Mohammadpour M. Progressive corneal vascularization caused by graft-versus-host disease. Cornea 2007;26:225-226.
11. Mittelviefhaus H, Auw-Hadrich C. Hornhautkomplikationen nach hamatopoetischer Stammzelltransplantation. Ophthalmologe 2003; 100: 222-229.
12. Reddy P, Ferrara J. Immunobiology of acute graft-versus-host disease. Blood Rev 2003; 17: 187-194.
13. Rojas B, Cuhna R, Zafirakis P, Ramirez JM, Lizan-garciia M, Zhao T et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res 2005; 81: 313-325.
14. Piper KP, Horlock C, Curnow J, Arrazi J, Nicholls S, Mahendra P et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem cell transplantation. Blood 2007; 110: 3827-3832.
15. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan M et al. Involvement of chemokine receptors in breast cancer metastasis. Nat Med 2001; 410: 50-56.
16. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-165.
17. Butcher E, Picker L. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
18. Zlotnik A, Yoshie O. Chemokines: A New Classification System and Their Role in Immunity. Immunity 2000; 12: 121-127.
19. Abu El-Asrar AM, Struyf S, Al-Kharashi SA, Missotten L, Van Damme J, Geboes K. Chemokines in the limbal form of vernal keratoconjunctivitis. Br J Ophthalmol 2000; 84: 1360-1366.
20. Abu El-Asrar A, Struyf S, Al-Mosallam AA, Missotten L, Van Damme J, Geboes K. Expression of chemokine receptors in vernal keratoconjunctivitis. Br J Ophthalmol 2001; 85: 1357-1361. (Pubitemid 33016120)
21. Yamagami S, Ebihara N, Yokoo S, Amano S. Chemokine receptor gene expression in giant papillae of atopic konjuncti- vitis. Mol Vis 2005; 11: 192-200.
22. Miyazaki D, Nakamura T, Komatsu N, Nawata N, Ikeda Y, Inoue Y et al. Roles of chemokines in ocular allergy and possible therapeutic strategies. Cornea 2004; 23 (Suppl 1): S48-S54.
23. Shirane J, Nakayama T, Nagakubo D, Izawa D, Hieshima K, Shimomura Y et al. Corneal epithelial cells and stromal keratocytes efficiently produce CC chemokine-ligand 20 (CCL20) and attract cells expressing its receptor CCR6 in mouse herpetic stromal keratitis. Curr Eye Res 2004; 28: 297-306.
24. Spandau U, Toksoy A, Verhaart S, Gillitzer R, Kruse F. High expression of chemokines Gro-alpha (CXCL-1), IL-8 (CXCL- 8), and MCP-1 (CCL-2) in inflamed human corneas in vivo. Arch Ophthalmol 2003; 121: 825-831.
25. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano Aea. Expression of IP-10/CXCL10 and MIG/ CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002; 161: 195-206.
26. Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino M, Bendtzen Kea. Serum concentrations of the interferon- gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45: 1107-1121.
27. Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I, Rieker J et al. Ultraviolet radiation-induced injury, chemo- kines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005; 52: 1504-1516.
28. Ichiba T, Teshima T, Kuick R, Misek D, Liu C, Takada Y et al. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood2003; 102: 763-771.
29. New J, Li B, Koh W, Ng H, Tan S, Yap E et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002; 29: 979-986.
30. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
31. Gratwohl A, Brand R, Apperley J, v Biezen A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
32. Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol 1998; 82: 666-675.
33. Afonso AA, Monroy D, Stern ME, Feuer WJ, Tseng SC, Pflugfelder SC. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999; 106: 803-810.
34. Lee SH, Tseng SC. Rose bengal staining and cytologic characteristics associated with lipid tear deficiency. Am J Ophthalmol 1997; 124: 736-750.
35. Koch JM, Bornfeld N, Waubke TN, Wessing A. Impression cytology of the conjunctiva after high-dose brachytherapy of malignant melanomas of the uvea with 106Ru/106Rh-plaques. Fortschr Ophthalmol 1988; 85: 642-645.
36. Meller S, Lauerma A, Kopp F, Winterberg F, Anthoni M, Muller A et al. Chemokine responses distinguish chemical- induced allergic from irritant skin inflammation: memory T cells make the difference. J Allergy Clin Immunol 2007; 119: 1470-1480.
37. Yang Y, Wang H, Asavaroengchai W, Dey B. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol 2005; 2: 323-329.
38. Farber J. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-257.
39. Cole K, Strick C, Paradis T, Ogborne K, Loetscher M, Gladue R et al. Interferon-inducible T cell alpha chemoattractant (I- TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021.
40. Serody J, Burkett S, Panoskaltsis-Mortari A. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8( + ) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-2980.
41. Faaij C, Lankester A, Spierings E, Hoogeboom M, Bowman E, Bierings M et al. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4+ T cells to skin in human graft- versus-host disease. Br J Haematol 2006; 133: 538-549.
42. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007; 127: 281-292.
43. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito M, Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus- host disease in mice. J Immunol 2003; 170: 588-596.
44. Serody J, Cook D, Kirby S, Reap E, Shea T, Frelinger J. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 1999; 93: 43-50.